Markets

Sector Update: Healthcare Shares Higher; Lexicon Sinks 15% on Study of Ulcerative Colitis Treatment

Healthcare stocks:

JNJ: flat

PFE: +0.14%

ABT: +0.27%

MRK: +0.04%

AMGN: -0.06%

Healthcare shares are generally higher in pre-market, although Lexicon Pharmaceuticals, Inc. ( LXRX ) is down 15% today after it announced top-line results from a pilot study exploring the use of telotristat etiprate in ulcerative colitis.

Telotristat etiprate did not prove to have "a large impact on disease modification." Telotristat etiprate, a serotonin synthesis inhibitor, is currently in Phase 3 development for carcinoid syndrome, a condition caused by metastatic, functioning neuroendocrine tumors.

And LDR Holding ( LDR ) said it has priced its initial public offering of 5 million shares at $15 per share. The maker of medical devices for proprietary spinal surgery technologies said underwriters have a 30-day option to buy an additional 750,000 shares to cover any overallotments.

The shares will begin trading on the Nasdaq stock market under the ticker LDRH today. The offer is expected to close on Oct. 15.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LXRX

Other Topics

Commodities

Latest Markets Videos